Comparative Pharmacology
Head-to-head clinical analysis: AK FLUOR 25 versus CYSVIEW KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AK FLUOR 25 versus CYSVIEW KIT.
AK-FLUOR 25% vs CYSVIEW KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sodium fluorescein absorbs light in the blue spectrum (465-490 nm) and emits yellow-green fluorescence (520-530 nm), enabling visualization of the retinal and choroidal vasculature by highlighting areas of vascular leakage, staining defects, or filling defects.
Cholic acid is a primary bile acid that acts as a choleretic and bile acid replacement therapy. It competitively inhibits hepatic bile acid synthesis via negative feedback on cholesterol 7α-hydroxylase (CYP7A1), reducing the production of toxic bile acid intermediates in patients with inborn errors of bile acid synthesis.
Intravenous administration: 5-15 mg/kg as a single bolus injection over 1-2 minutes. For ophthalmic use: 1-2 drops of 2% fluorescein solution topically.
Intravenous: 5 mg/kg as a single dose administered over 30 minutes.
None Documented
None Documented
Terminal half-life: 1-2 minutes (fluorescence decay); clinical context: transient plasma fluorescence, minimal systemic accumulation
Terminal elimination half-life: 1.9-2.5 hours (mean 2.1 h) in normal renal function; prolonged in renal impairment (up to 20 h in ESRD).
Renal: >90% unchanged within 24-48 hours; <10% fecal via biliary elimination
Renal: 90% unchanged via glomerular filtration; biliary/fecal: <5%
Category C
Category C
Diagnostic Dye
Diagnostic Dye